中华肝脏病杂志
中華肝髒病雜誌
중화간장병잡지
CHINESE JOURNAL OF HEPATOLOGY
2012年
1期
17-19
,共3页
张平%陆伟%李顺天%尤炜%张玉荣%陈静
張平%陸偉%李順天%尤煒%張玉榮%陳靜
장평%륙위%리순천%우위%장옥영%진정
肝炎病毒,乙型%肝炎e抗原,乙型%治疗
肝炎病毒,乙型%肝炎e抗原,乙型%治療
간염병독,을형%간염e항원,을형%치료
Hepatitis B virus%Hepatitis B e antigens%Therapy
目的 根据新生儿出生时HBsAg和HBV DNA的载量,调整人乙型肝炎免疫球蛋白使用量,以期更有效地阻断HBV的母婴传播. 方法 收集出生2h内静脉血HBsAg阳性新生儿资料125例.分为研究组64例,对照组61例,研究组根据新生儿出生时HBsAg感染量调整乙型肝炎免疫球蛋白使用量,与对照组比较新生儿12个月龄以上治疗效果.计量资料采用非正态分布采用秩和检验,计数资料采用x2检验.结果 2组新生儿出生时HBsAg和HBV DNA检测值的差异均无统计学意义(p 值均＞0.05).研究组出生HBV感染新生几64例,12月龄以上成功清除HBsAg者53例,成功清除率为82.8％,感染11例(1.2％).对照组出生HBV感染新生儿61例,12月龄以上成功清除HBsAg者35例,成功清除率为57.4％,感染26例(3.1％).2组出生HBV感染新生儿12个月龄以上清除HBsAg效果比较,x2=9.696,P＜0.05,差异有统计学意义.结论 根据新生儿的HBsAg感染量调整使用乙型肝炎免疫球蛋白,可提高乙型肝炎母婴传播的阻断成功率.
目的 根據新生兒齣生時HBsAg和HBV DNA的載量,調整人乙型肝炎免疫毬蛋白使用量,以期更有效地阻斷HBV的母嬰傳播. 方法 收集齣生2h內靜脈血HBsAg暘性新生兒資料125例.分為研究組64例,對照組61例,研究組根據新生兒齣生時HBsAg感染量調整乙型肝炎免疫毬蛋白使用量,與對照組比較新生兒12箇月齡以上治療效果.計量資料採用非正態分佈採用秩和檢驗,計數資料採用x2檢驗.結果 2組新生兒齣生時HBsAg和HBV DNA檢測值的差異均無統計學意義(p 值均＞0.05).研究組齣生HBV感染新生幾64例,12月齡以上成功清除HBsAg者53例,成功清除率為82.8％,感染11例(1.2％).對照組齣生HBV感染新生兒61例,12月齡以上成功清除HBsAg者35例,成功清除率為57.4％,感染26例(3.1％).2組齣生HBV感染新生兒12箇月齡以上清除HBsAg效果比較,x2=9.696,P＜0.05,差異有統計學意義.結論 根據新生兒的HBsAg感染量調整使用乙型肝炎免疫毬蛋白,可提高乙型肝炎母嬰傳播的阻斷成功率.
목적 근거신생인출생시HBsAg화HBV DNA적재량,조정인을형간염면역구단백사용량,이기경유효지조단HBV적모영전파. 방법 수집출생2h내정맥혈HBsAg양성신생인자료125례.분위연구조64례,대조조61례,연구조근거신생인출생시HBsAg감염량조정을형간염면역구단백사용량,여대조조비교신생인12개월령이상치료효과.계량자료채용비정태분포채용질화검험,계수자료채용x2검험.결과 2조신생인출생시HBsAg화HBV DNA검측치적차이균무통계학의의(p 치균＞0.05).연구조출생HBV감염신생궤64례,12월령이상성공청제HBsAg자53례,성공청제솔위82.8％,감염11례(1.2％).대조조출생HBV감염신생인61례,12월령이상성공청제HBsAg자35례,성공청제솔위57.4％,감염26례(3.1％).2조출생HBV감염신생인12개월령이상청제HBsAg효과비교,x2=9.696,P＜0.05,차이유통계학의의.결론 근거신생인적HBsAg감염량조정사용을형간염면역구단백,가제고을형간염모영전파적조단성공솔.
Objective To determine the effective dose of hepatitis B immunoglobulin (HBIG) for clearing maternally-transmitted hepatitis B virus (HBV) fiom a newborn.Methods Full-term neonates born to HBV-infected mothers were tested for hepatitis B surface antigen (HBsAg) and HBV DNA in venous blood,Individuals with positive results within two hours after birth were selected for study,and divided among two treatment groups: research group receiving HBIG continually adjusted to quantitative levels of neonatal HBsAg and HBV DNA levels; control group receiving standard HBIG 200IU dose.All neonates were also treated with 10 micrograms of recombinant vaccine.The decreases in HBsAg and HBV DNA over 12 months were comparatively analyzed between the two treatment groups.Results The two treatment groups (HBIG adjusted vs.standard) were statistically similar in Apgar score (9.38 ± 0.49 vs.9.37 ± 0.48),neonate body weight (3458.67 + 374.93 vs.3558.61 ± 322.85 g),maternal age (26.33 ± 3.63 vs.25.33 ± 3.03),and initial HBsAg and HBV DNA levels (rank sum test Z=1.381,and Z=0.700,respectively) (all,P＞ 0.05).Successful clearance of HBV infection within 12 months was achieved in significantly more neonates in the HBIG adjusted therapy group than in the standard therapy group (82.8％ vs.57.4％; x2 =9.696,P ＜ 0.05).Condusion Adjusting the neonatal HBIG dose according to HBsAg and HBV DNA levels can improve the success rate of clearing maternally-transmitted HBV.
